Vismodegib in PAMAM-dendrimers for potential theragnosis in skin cancer

Vismodegib (VDG) is an antineoplastic, a first-in-class Hedgehog signaling pathway inhibitor, indicated to treat locally advanced or metastatic basal cell carcinoma. Treatment with this drug was approved in 2012 by the US-FDA for oral administration (dose of 150 mg per day) in patients with a refusa...

Full description

Bibliographic Details
Published in:OpenNano
Main Authors: David E. Ybarra, Maria Natalia Calienni, Luis Felipe Barraza Ramirez, E. Tais Aguayo Frias, Cristian Lillo, Silvia del Valle Alonso, Jorge Montanari, Fernando C. Alvira
Format: Article
Language:English
Published: Elsevier 2022-07-01
Subjects:
Vismodegib
PAMAM dendrimers
Basal cell carcinoma
Skin delivery
Online Access:http://www.sciencedirect.com/science/article/pii/S2352952022000160

Internet

http://www.sciencedirect.com/science/article/pii/S2352952022000160

Similar Items